Stemina works on the discovery, development, and commercialization of molecular biomarkers to improve drug safety and human health.
Stemina’s cell-based assays use two innovative technologies: human embryonic stem (hES) cells and metabolomics. Stemina uses mass spectrometry to analyze the small molecules secreted by hES cells in response to drugs, injury, or disease. We also use differentiated cells, like heart or neural cells made from hES cells and induced pluripotent stem (iPS) cells.
Create Success — Work with Stemina
Customize Your Stemina Experience
Begin with a discussion of the project workflow with the Stemina team. By working together, we can ensure that the experimental design is focused and the studies are powered appropriately to yield the desired outcomes.
Your material is at work in Stemina labs
Once we agree on the study design, an experienced scientific project manager is assigned and your work is scheduled. During the project, we check in frequently to update you on the progress.
Stemina algorithms work to process your data
The team, led by the project manager, includes members of Stemina’s scientific leadership from biology, analytical technology, toxicology, and informatics. The core team stays with the project throughout the process to ensure a seamless experience.
Consult with Stemina to interpret your results
A detailed report, which contains a summary of the data and the results, is prepared. In addition, we present and discuss the results with you so you can take advantage of Stemina’s experience in metabolomics and to maximize the value of the work.
Our History
Stemina Biomarker Discovery was established in November 2006 and co-founded by Elizabeth Donley, JD, MBA, MS and Gabriela Cezar, DVM, PhD. Stemina’s technology arose from the pioneering work of Dr. Cezar at the University of Wisconsin-Madison. Stemina opened its doors in its current location in Madison, Wisconsin on November 1, 2007.
The company’s first commercial product, devTOX quickPredict, is a screening assay that uses human embryonic stem cells or induced pluripotent stem cells to screen drug candidates, chemicals, consumer products, and cosmetics for their potential effect on the developing human embryo.
Development of Cardio quickPredict, an assay that screens for cardiotoxicity, followed and has been peer-reviewed and published in large studies in leading toxicology journals. All continue the idea of bringing stem cell biology and metabolomics together for biomarker discovery.
The Stemina team has grown, adding skilled staff to the toxicology company and the neurological disorders division, which was launched in 2014. Stemina and NeuroPointDX continue to innovate with new applications for our human, cell based tests.
European Partner
The CiToxLAB Group (now a part of Charles River) offers a comprehensive range of preclinical and specialty safety evaluation services from its facilities in France, Canada, Denmark, and Hungary. CiToxLAB is a leading preclinical service company offering a wide range of drug development services across a global network. CiToxLAB offers a wealth of experience and performs comprehensive services in all areas of preclinical drug development for the pharmaceutical, biotechnology, chemical, agrochemical, and consumer product industries.